INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 175 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2014. The put-call ratio across all filers is 1.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2020 | $519,000 | -44.4% | 10,837 | -27.0% | 0.00% | -50.0% |
Q1 2020 | $934,000 | -53.3% | 14,837 | -8.1% | 0.00% | -33.3% |
Q4 2019 | $2,000,000 | +249.0% | 16,137 | +86.8% | 0.00% | +200.0% |
Q3 2019 | $573,000 | -24.5% | 8,637 | -9.4% | 0.00% | 0.0% |
Q2 2019 | $759,000 | -26.2% | 9,537 | +3.7% | 0.00% | -50.0% |
Q1 2019 | $1,029,000 | +136.6% | 9,200 | +130.0% | 0.00% | +100.0% |
Q4 2016 | $435,000 | -33.9% | 4,000 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $658,000 | -33.3% | 4,000 | -39.4% | 0.00% | -50.0% |
Q4 2015 | $986,000 | -11.3% | 6,600 | -1.5% | 0.00% | 0.0% |
Q3 2015 | $1,111,000 | -29.2% | 6,700 | +3.1% | 0.00% | -33.3% |
Q2 2015 | $1,569,000 | -19.4% | 6,500 | -5.8% | 0.00% | -25.0% |
Q1 2015 | $1,946,000 | +190.0% | 6,900 | +60.5% | 0.00% | +300.0% |
Q4 2014 | $671,000 | -34.1% | 4,300 | 0.0% | 0.00% | -50.0% |
Q3 2014 | $1,018,000 | -57.0% | 4,300 | -57.0% | 0.00% | -50.0% |
Q2 2014 | $2,366,000 | -42.1% | 10,000 | -19.4% | 0.00% | -42.9% |
Q1 2014 | $4,089,000 | – | 12,400 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WHITE SQUARE CAPITAL LLP | 65,500 | $7,117,000 | 11.05% |
Ghost Tree Capital, LLC | 70,000 | $7,606,000 | 1.83% |
Carmignac Gestion | 2,022,792 | $219,776,000 | 1.71% |
Orbimed Advisors | 1,120,000 | $121,688,000 | 1.55% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 29,555 | $3,211,000 | 1.45% |
Parametrica Management Ltd | 10,814 | $1,175,000 | 1.16% |
BB BIOTECH AG | 255,719 | $27,784,000 | 1.03% |
SECTORAL ASSET MANAGEMENT INC | 74,150 | $8,056,000 | 0.89% |
ALTRINSIC GLOBAL ADVISORS LLC | 188,904 | $20,524,000 | 0.76% |
FALCON POINT CAPITAL, LLC | 45,005 | $4,890,000 | 0.66% |